Iwona Lugowska, Head of the Center of Excellence in Precision Oncology at Maria Sklodowska-Curie National Research Institute of Oncology, shared post on linkedIn, adding:
“With great pride I would like to highlight the achievement of my PhD student, Izabela Maria Agnieszczak, who represented our Institute at ESMO MAP 2025 in Paris with a poster summarising results from the first Polish early-phase clinical trials unit established at the Maria Skłodowska-Curie National Research Institute of Oncology.
This recognition reflects not only her talent and dedication, but also the growing role of young researchers in shaping the future of precision oncology. Izabela’s work illustrates the potential impact of early-phase clinical research, especially for patients with rare and hard-to-treat cancers.
Congratulations, Izabela – I am proud of your commitment, scientific curiosity.”
Quoting Maria Skłodowska-Curie National Research Institute of Oncology’s post:
“We are proud to announce that Dr. Izabela Maria Agnieszczak represented our Institute during the MAP (Molecular Analysis for Precision Oncology) 2025 ESMO in Paris, a prestigious congress dedicated to precision oncology.
Izabela presented a poster summarizing the results of patient treatment in the first Polish center dedicated to early-stage research, founded in 2017 in Maria Sklodowska-Curie National Research Institute of Oncology. This is a unique distinction that emphasizes both the scientific potential and the commitment of the young researcher.
‘Presenting the first results of our project at one of the most important congresses on precision oncology is a unique experience for me. The opportunity to talk to eminent experts about the directions of further analysis was extremely valuable. I am coming back with a new motivation to work on this issue. This meeting confirmed my belief that our project has the potential to make an important contribution to the international discussion on the role of early-stage research in oncology, especially in the context of Central and Eastern European countries,’ says Izabela.
The poster summarizes the results of early-stage clinical trials between 2017 and 2023, focusing on the treatment outcomes of patients in whom, in most cases, standard treatment has proven insufficient. The results are promising – about a quarter of patients responded to treatment with experimental therapy in the form of a reduction in cancerous lesions, and in individual cases even complete remission was observed. This is an important proof that the research conducted at our Institute remains at the level of leading international centers and has a real impact on the lives of patients.
The co-authors of the paper included outstanding experts of the National Institute of Electrical and Electronic Research, m.in. Dr hab. n. med. Beata Jagielska – director of the Institute, Prof. Piotr Rutkowski, Prof. Iwona Lugowska, MD, PhD and Katarzyna Kozak, MD, PhD. Izabela’s joining such an experienced team highlights her scientific potential and readiness to pursue ambitious research projects.
The study was carried out as part of the internal NIO-NRI Curie4Curie grant.
The trip was co-financed by the PTOK Scholarship Fund.
Consultations at the Early Phase Research Department can be arranged by phone: +48 22 546 33 81.”
More posts featuring Iwona Lugowska.
